KOPRAN
Kopran Limited (KOPRAN) Stock Analysis
Kopran Limited manufactures pharmaceutical formulations and APIs for domestic and export markets. It has plants in Maharashtra supplying generics and contract products. The company serves regulated and semi-regulated countries. It is a listed pharma company.
Healthcare › Drug Manufacturers - General
₹282.00
+19.86% 1W | +60.40% 52W
Market Cap
1.4k CR
P/E Ratio
54.3
52W High
₹286.5
52W Low
₹107
Div. Yield
1.08%
Beta
0.9
50 DMA
₹208.5
200 DMA
₹165.9
Profit Margin
3.6%
Inst. Own.
0.2%
🚀 BREAKOUT
🚀 BREAKOUT
Fundamentals
Profit & Loss
| Metric | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 117.00 | 152.59 | 158.92 | 186.08 | 139.44 | 151.56 | 166.24 | 172.36 | 135.22 | 117.91 | 194.28 | 234.02 | 153.99 |
| Expenses | 110.69 | 129.76 | 135.34 | 164.39 | 121.28 | 136.83 | 146.39 | 155.27 | 121.09 | 123.19 | 176.52 | 201.08 | 138.18 |
| Operating Profit | 6.31 | 22.83 | 23.58 | 21.69 | 18.16 | 14.73 | 19.85 | 17.09 | 14.13 | -5.28 | 17.76 | 32.94 | 15.81 |
| OPM % | 5.39% | 14.96% | 14.84% | 11.66% | 13.02% | 9.72% | 11.94% | 9.92% | 10.45% | -4.48% | 9.14% | 14.08% | 10.27% |
| Other Income | 2.39 | 0.13 | 2.43 | 9.67 | 2.63 | 1.00 | 0.17 | 3.26 | 2.56 | 0.03 | 0.07 | 0.09 | 2.05 |
| Interest | 1.83 | 1.94 | 2.24 | 2.59 | 2.18 | 2.23 | 2.16 | 2.77 | 2.54 | 2.09 | 2.67 | 3.17 | 3.28 |
| Depreciation | 3.26 | 2.77 | 3.27 | 3.59 | 3.87 | 3.85 | 4.00 | 3.87 | 4.26 | 4.28 | 4.42 | 4.52 | 5.77 |
| Profit before tax | 3.61 | 18.25 | 20.50 | 25.18 | 14.74 | 9.65 | 13.86 | 13.71 | 9.89 | -11.62 | 10.74 | 25.34 | 8.81 |
| Tax % | 22.99% | 24.55% | 23.02% | 26.01% | 24.69% | 23.42% | 24.96% | 29.39% | 24.67% | -14.63% | 13.04% | 25.57% | 23.84% |
| Net Profit | 2.77 | 13.77 | 15.79 | 18.62 | 11.10 | 7.38 | 10.40 | 9.68 | 7.45 | -9.92 | 9.34 | 18.87 | 6.70 |
| EPS in Rs | 0.57 | 2.86 | 3.28 | 3.86 | 2.30 | 1.53 | 2.16 | 2.01 | 1.54 | -2.06 | 1.94 | 3.91 | 1.39 |
| Metric | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 326 | 296 | 310 | 313 | 358 | 360 | 492 | 478 | 551 | 615 | 630 | 681 | 700 |
| Expenses | 294 | 266 | 274 | 283 | 312 | 313 | 410 | 390 | 499 | 540 | 557 | 619 | 639 |
| Operating Profit | 31 | 30 | 36 | 31 | 46 | 47 | 82 | 87 | 52 | 74 | 73 | 62 | 61 |
| OPM % | 10% | 10% | 12% | 10% | 13% | 13% | 17% | 18% | 9% | 12% | 12% | 9% | 9% |
| Other Income | -48 | 1 | 11 | 9 | 3 | -0 | 18 | 11 | 3 | 15 | 4 | 0 | 2 |
| Interest | 13 | 13 | 14 | 9 | 9 | 9 | 6 | 5 | 6 | 9 | 9 | 10 | 11 |
| Depreciation | 10 | 8 | 8 | 9 | 9 | 10 | 10 | 11 | 13 | 13 | 16 | 17 | 19 |
| Profit before tax | -39 | 11 | 25 | 23 | 32 | 28 | 83 | 82 | 36 | 68 | 52 | 34 | 33 |
| Tax % | 0% | 0% | 20% | 10% | 24% | 26% | 26% | 25% | 24% | 25% | 26% | 25% | |
| Net Profit | -39 | 11 | 20 | 20 | 24 | 21 | 62 | 61 | 27 | 51 | 39 | 26 | 25 |
| EPS in Rs | -9.52 | 2.48 | 4.60 | 4.74 | 5.55 | 4.86 | 14.24 | 12.66 | 5.65 | 10.57 | 7.99 | 5.33 | 5.18 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 21% | 24% | 53% | 28% | 38% | 56% |
Growth — CAGR
| Metric | 3Y | 5Y | 10Y |
|---|---|---|---|
| Revenue CAGR | 7.0% | 7.0% | 9.0% |
| Profit CAGR | -2.0% | -16.0% | 8.0% |
Shareholding Pattern
Promoters44.43%
FIIs0.76%
Public54.81%
Promoters44.43%
FIIs0.60%
Public54.99%
Promoters44.43%
FIIs0.36%
Public55.21%
Promoters44.43%
FIIs0.57%
Public55.01%
Promoters44.43%
FIIs0.51%
Public55.06%
Promoters44.29%
FIIs0.41%
DIIs0.14%
Public55.15%
Promoters44.49%
FIIs0.84%
DIIs1.20%
Public53.47%
Promoters44.42%
FIIs1.11%
Public54.45%
Promoters44.43%
FIIs0.57%
Public55.01%
Promoters44.43%
FIIs0.51%
Public55.06%
KOPRAN
Holdings Analysis
Key strengths & risk signals
69
Overall
43
Fundamental
96
Technical
Risks (2)
Cannot calculate PEG - insufficient growth data.
OVERBOUGHT! RSI at 81.5 - caution, may pull back.
Strengths (4)
PERFECT RECORD! Revenue has grown consistently every year. Exceptional business stability.
BULLISH TREND! 50-day average (208.5) is above 200-day average (165.9) - positive signal.
BREAKOUT! Stock has broken above resistance levels with momentum.
EXCELLENT YEAR! Stock gained 60.4% in the last year.
Fundamental & Technical Analysis
69Overall
43Fundamental
96Technical
Fundamental Breakdown
Growth Quality
10/30
Revenue CAGR: 7.2% (MODERATE, 8/15). Profit CAGR: -1.9% (DECLINING, 2/15).
Profit Margin
2/10
LOW MARGIN! 3.6% profit margin - thin profits.
PEG Valuation
1/10
Cannot calculate PEG - insufficient growth data.
Dividend Yield
5/10
LOW DIVIDEND! 1.08% yield - minimal income contribution.
Debt to Equity
10/10
VERY LOW DEBT! D/E of 0.00 - excellent financial health.
Public Holding
5/20
TOO MUCH PUBLIC HOLDING! 55.03% public ownership - higher volatility risk.
Stability Index
10/10
PERFECT RECORD! Revenue has grown consistently every year. Exceptional business stability.
Technical Breakdown
Moving Averages
12/10
BULLISH TREND! 50-day average (208.5) is above 200-day average (165.9) - positive signal.
Price Position
8/10
STRONG POSITION! Current price (282.0) is above both moving averages.
Trend Pattern
20/20
BREAKOUT! Stock has broken above resistance levels with momentum.
52W Performance
10/10
EXCELLENT YEAR! Stock gained 60.4% in the last year.
Volume Sentiment
30/30
BULLISH SENTIMENT! In last 30 days: 17 up days, 13 down days. Avg volume on up days: 2,610,474 vs down days: 240,564. Ratio: 10.85x
RSI
2/5
OVERBOUGHT! RSI at 81.5 - caution, may pull back.
52W Range
5/5
STRONG! Trading at 97.5% of 52W range - near yearly highs.
Momentum
5/5
STRONG MOMENTUM! Price has grown across all timeframes - up 19.9% (1 week), 41.2% (1 month), 42.8% (3 months). Momentum is accelerating.
Beta
4/5
BELOW MARKET! Beta of 0.90 - slightly less volatile than market.
Peer Comparison
Healthcare · Drug Manufacturers - General · 8 stocks
| Stock | Price | P/E | Profit Margin | Revenue CAGR 5Y | Profit CAGR 5Y | 52W Change | Stock Strength | Trendline | YoY Profit | QoQ Profit | YoY Revenue | QoQ Revenue |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| KOPRAN | ₹282.00 | 54.3 | 3.6% | 7.2% | -1.9% | +60.4% | 69 | BREAKOUT | -9.5% | -64.6% | +13.9% | -34.2% |
| TTKHLTCARE | ₹1,073.30 | 20.5 | 8.3% | 5.9% | -53.2% | -11.8% | 61 | BREAKDOWN | +63.8% | -2.3% | +13.8% | +18.2% |
| NGLFINE | ₹2,724.00 | 29.4 | 10.7% | 21.8% | 32.9% | +94.5% | 80 | BOUNCE FROM SUPPORT | +100.0% | +36.3% | +33.6% | -6.7% |
| SAIPARENT | ₹508.60 | 114.5 | 3.9% | 126.1% | 111.8% | +25.9% | 69 | BREAKDOWN | +464.3% | -1,416.7% | +435.0% | -33.6% |
| SMSPHARMA | ₹467.40 | 42.2 | 11.4% | 19.3% | – | +56.3% | 77 | BREAKOUT | +2.0% | -36.1% | +5.6% | -13.0% |
| CORONA | ₹2,210.00 | 67.8 | 13.5% | 16.6% | 29.7% | +53.1% | 85 | BREAKOUT | +29.9% | +32.5% | +21.9% | +19.5% |
| SENORES | ₹1,395.90 | 49.3 | 18.7% | 159.1% | 139.2% | +98.6% | 77 | BREAKDOWN | +55.8% | -2.8% | +35.9% | +2.9% |
| SANOFI | ₹3,077.20 | 21.9 | 17.9% | -12.6% | -19.3% | -38.5% | 52 | BREAKDOWN | +20.1% | -18.6% | +7.7% | -7.3% |
Data from TradeAlone · Updated daily
